Alzheimer's Disease Treatments
The UCLA Amyloid Immunotherapy Care Program
The UCLA Amyloid Immunotherapy Care (AIC) Program is at the forefront of Alzheimer’s disease to target amyloid-beta plaques. The program is to advance the development of effective immunotherapies that could potentially slow or halt Alzheimer's progression.
Learn more about the AIC Program
Donanemab
The FDA has fully approved donanemab (Kisunla™) for eligible patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease based on a reduction in amyloid-β(p3-42) plaques observed in patients treated with this medication during clinical trials. It is administered as infusions once a month for up to 18 months. Patients may have the option to stop treatment upon reaching a threshold clearance of amyloid beginning after 9 months of treatment.
Lecanemab
The FDA has fully approved lecanemab (Leqembi®) for eligible patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease based on a reduction in amyloid plaques observed in patients treated with this medication during clinical trials. It is administered as infusions every two weeks.